Merck Buys Out Blood Cancer Biotech Imago for $1.35B

Imago BioSciences, a bone marrow disorder-focused biotech based out of California, is being scooped up by Merck & Co. for $1.35 billion in an all-cash deal. Imago’s flagship drug, bomedemstat, is clearly the impetus for the lucrative transaction...